Definitive Contract HHSN261201300077C

This is a $389,973 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Ai Biosciences, Inc., a small disadvantaged biotechnology company. The contract is for the development of a "Rapid Isothermal Amplification Chip for HPV Detection and Genotyping in Low-Resource Settings." This aligns with NCI's mission to support cancer research and diagnostic technologies,...

This is a $382,034 Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Phoenix Biosystem, Inc., a self-certified small disadvantaged business. The contract is for the development of HPV point-of-care molecular diagnostics for low- and middle-income countries. The original pre-solicitation announced that NIH and CDC were seeking SBIR proposals to advance their infectious...

This is a $200,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Nanomaterial Innovation LTD, a woman-owned limited liability company. The contract is for the development of "MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY", which aligns with NCI's research focus on cancer therapeutics. The contract has a firm fixed price pricing type and was awarded on September 24, 2010 with a...

<p>The National Cancer Institute awarded a definitive contract to Pathrx, Inc. for biomedical basic research under SBIR Topic 309 Phase II on September 22, 2015, with a ceiling value of $977,245.04.</p> <p>The contract funds research on high-density RT-PCR arrays for cancer diagnosis and prognosis. Performance runs from September 22, 2015 through September 21, 2017, and is priced on a cost-plus-fixed-fee basis. Place of performance is Watertown, MA.</p>

This federal contract award, with an ID of 75N91021P00756, was issued by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The $95,995 firm-fixed-price purchase order was awarded to Atila Biosystems Incorporated, a small business, to provide HPV genotyping assays and testing supplies to support the NCI's Division of Cancer Epidemiology and Genetics (DCEG) research efforts. The contract was...

The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $223,412 Small Business Innovation Research (SBIR) Program Phase I contract to Qrono, Inc. for the development of a &quot;Failed Tubulin Inhibitor Reformulated as Localized Adjuvant Therapy for Head and Neck Cancer.&quot; This Firm Fixed Price contract with a completion date of September 30, 2015 aims to advance an innovative approach to treating head and neck cancer by reformulating a...

This is a $182,050 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanoivd, Inc., a small disadvantaged, woman-owned business. The contract is for TAS::75 0849::TAS and has a total small business set-aside designation. The period of performance runs from the award date of September 30, 2010 through the ultimate completion date of March 30, 2011. Nanoivd, Inc. is the prime contractor, and no subcontractors are mentioned. The contract...

This is a $1,199,956.00 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanovector Incorporated. The contract is for &quot;OTHER FUNCTIONS TOPIC 267, MULTIFUNCTIONAL THERAPEUTICS USING ENGINEERED PLANT VIRUS NANOPARTICLES&quot; and was set aside for small businesses. The contract has an ultimate completion date of September 27, 2014 and was awarded on September 28, 2012. This contract appears to be part of the NCI's research and development...

This definitive contract award of $13,720 by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Zymeron Corporation is for the research and development of a rapid point-of-care test to screen for human papillomavirus in low-resource settings. The contract is associated with Solicitation PHS-2023-1 of the NIH and Centers for Disease Control and Prevention Small Business Innovation Research Program Phase I, which sought proposals to address...

The National Cancer Institute awarded a $224,997.00 firm fixed-price definitive contract to Paganini Biopharma, Inc. for research and development in biomedical basic research. The contract has a performance period ending on September 17, 2015 and was awarded on September 18, 2014. This contract was not set aside for any specific business type. The National Cancer Institute is a civilian agency within the U.S. Department of Health and Human Services that conducts and supports cancer research.